Preclinical Amyotrophic Lateral Sclerosis (ALS) Studies
PsychoGenics leverages transgenic models to advance preclinical studies of amyotrophic lateral sclerosis (ALS), a progressive paralytic disorder characterized by motor...
Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity .
S. Stefanie, H Bettina, Nilges M, Schroeder S, Hoelich A, Keletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M,...
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More
By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with...
Preclinical Neuromuscular Disorders Research
PsychoGenics is at the forefront of preclinical neuromuscular disorders research, combining long-standing expertise with advanced scientific tools. Our dedication to...
Preclinical Neurodegenerative Disorders Research
PsychoGenics has established itself as a reputable partner in preclinical research for neurodegenerative disorders. Our depth of expertise in preclinical...
Preclinical Alzheimer’s Disease Studies
At PsychoGenics, our experienced scientists provide expert preclinical Alzheimer’s disease (AD) studies to develop your therapy. Our research focuses on...
Preclinical Parkinson’s Disease Studies
Parkinson’s disease is a chronic degenerative neurological disorder affecting millions globally. Its manifestation — the death of dopaminergic cells in...
Preclinical Huntington’s Disease Studies
Distinguished by the experience and knowledge of our scientists and technicians, PsychoGenics stands as a leading partner in preclinical Huntington’s...
Preclinical Spinal Muscular Atrophy (SMA) Studies
With a wealth of experience in preclinical spinal muscular atrophy (SMA) studies, PsychoGenics is an ideal choice to partner with...